Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Myovant Sciences was a clinical-stage biopharmaceutical company dedicated to redefining care for women and for men through science, medicines, and advocacy. It focused on developing and commercializing innovative therapies for women's health issues (like uterine fibroids and endometriosis) and prostate cancer. Key products included ORGOVYX® (relugolix) for advanced prostate cancer and MYFEMBREE® (relugolix, estradiol, and norethindrone acetate) for heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis. In March 2023, Myovant Sciences was acquired by Sumitovant Biopharma Ltd., a wholly-owned subsidiary of Sumitomo Pharma Co., Ltd. Myovant now operates as part of Sumitovant, continuing its mission within the larger Sumitomo Pharma group.
The Brisbane office served as the main hub for U.S. operations, including clinical development, commercial strategy, and corporate functions for Myovant Sciences before its acquisition.
Located within a prominent biotechnology hub in the San Francisco Bay Area, offering access to talent and industry collaboration.
Historically, Myovant fostered a patient-focused, science-driven, and collaborative work environment aimed at addressing unmet medical needs. This culture is now part of the broader Sumitovant ethos.
This location was central to Myovant's U.S. drug development, regulatory approvals, and commercial launch activities for its key products.
Before its acquisition by Sumitovant Biopharma, Myovant Sciences operated with a global outlook, primarily from its U.S. headquarters in Brisbane, California, and its international headquarters in Basel, Switzerland. Its functions included conducting global clinical trials across North America, Europe, and other regions, pursuing regulatory approvals in multiple countries, and building commercial capabilities for its products. These global operations and strategies are now part of Sumitovant Biopharma and its parent company, Sumitomo Pharma.
320 Corey Way, Suite 200
Brisbane
CA
USA
Address: Viaduktstrasse 8, 4051 Basel, Switzerland
This office was crucial for managing Myovant's ex-U.S. clinical trials, engaging with European regulatory bodies, and planning for potential international market access.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Myovant Sciences' leadership includes:
Myovant Sciences has been backed by several prominent investors over the years, including:
The most significant executive changes at Myovant Sciences in the past 12-24 months were linked to its acquisition by Sumitovant Biopharma, completed in March 2023. This led to the transition of the Myovant leadership team as the company was integrated into Sumitovant.
Discover the tools Myovant Sciences uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition, Myovant Sciences likely utilized standard corporate email formats. For instance, common patterns include first name initial followed by last name, or first name separated from last name by a period, at the 'myovant.com' domain. Post-acquisition, communications would originate from Sumitovant or Sumitomo Pharma domains.
[first].[last]@myovant.com or [first_initial][last]@myovant.com
Format
jane.doe@myovant.com
Example
5%
Success rate
Sumitomo Pharma Press Release • March 7, 2023
Sumitovant Biopharma Ltd., a wholly-owned subsidiary of Sumitomo Pharma Co., Ltd., announced the successful completion of its acquisition of Myovant Sciences Ltd. As a result, Myovant became a wholly-owned subsidiary of Sumitovant and its shares ceased trading on the New York Stock Exchange....more
Myovant Sciences Press Release (via PR Newswire) • January 30, 2023
Myovant Sciences announced it had entered into a definitive agreement with Sumitovant Biopharma Ltd. under which Sumitovant would acquire all outstanding shares of Myovant not already owned by Sumitovant for $27.00 per share in cash. This valued Myovant at approximately $1.7 billion....more
Myovant Sciences Website (Archived News) • August 5, 2022
Myovant Sciences and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis in pre-menopausal women for up to 24 months....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Myovant Sciences, are just a search away.